A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients

G. Giaccone; E. F. Smit; J. P. Van Meerbeeck; T. Splinter; R. P. Golding; H. M. Pinedo; D. Laan; H. Van Tinteren; P. E. Postmus

doi:10.1023/A:1008321000887

A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients

G. Giaccone, E. F. Smit, J. P. Van Meerbeeck, T. Splinter, R. P. Golding, H. M. Pinedo, D. Laan, H. Van Tinteren, P. E. Postmus

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

Abstract

Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m²) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m² on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m² paclitaxel with gemcitabine 1000 mg/m² in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.

Original language	English
Pages (from-to)	109-112
Number of pages	4
Journal	Annals of Oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1023/A:1008321000887
Publication status	Published - 2000
Externally published	Yes

Keywords

Chemotherapy
Gemcitabine
Non-small-cell lung cancer
Paclitaxel

Access to Document

10.1023/A:1008321000887

Cite this

@article{e0171c34d521413280f4a39bc83b1caa,

title = "A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients",

abstract = "Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.",

keywords = "Chemotherapy, Gemcitabine, Non-small-cell lung cancer, Paclitaxel",

author = "G. Giaccone and Smit, {E. F.} and {Van Meerbeeck}, {J. P.} and T. Splinter and Golding, {R. P.} and Pinedo, {H. M.} and D. Laan and {Van Tinteren}, H. and Postmus, {P. E.}",

year = "2000",

doi = "10.1023/A:1008321000887",

language = "English",

volume = "11",

pages = "109--112",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "1",

}

TY - JOUR

T1 - A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients

AU - Giaccone, G.

AU - Smit, E. F.

AU - Van Meerbeeck, J. P.

AU - Splinter, T.

AU - Golding, R. P.

AU - Pinedo, H. M.

AU - Laan, D.

AU - Van Tinteren, H.

AU - Postmus, P. E.

PY - 2000

Y1 - 2000

N2 - Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.

AB - Thirty patients with chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) were given escalating doses of paclitaxel (150, 175, 200 mg/m2) on day 1 in three consecutive cycles, together with a fixed dose of gemcitabine 1000 mg/m2 on days 1 and 8; cycles were repeated every three weeks. The dose escalation of paclitaxel was feasible in the majority of patients. Subsequently, 30 other NSCLC patients received a dose of 200 mg/m2 paclitaxel with gemcitabine 1000 mg/m2 in a phase II study. The major side effect was mild myelosuppression. A response rate of 24% was achieved in 49 fully evaluable patients. This regimen proved to be safe and easy to administer on an out-patient setting, and constitutes now one of the arms of the current EORTC randomized study for advanced NSCLC.

KW - Chemotherapy

KW - Gemcitabine

KW - Non-small-cell lung cancer

KW - Paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=0033952737&partnerID=8YFLogxK

U2 - 10.1023/A:1008321000887

DO - 10.1023/A:1008321000887

M3 - Article

C2 - 10690398

AN - SCOPUS:0033952737

SN - 0923-7534

VL - 11

SP - 109

EP - 112

JO - Annals of Oncology

JF - Annals of Oncology

IS - 1

ER -

A phase I-II study of gemcitabine and paclitaxel in advanced non-small- cell lung cancer patients

Abstract

Keywords

Access to Document

Fingerprint

Cite this